We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| BioNTech SE | NASDAQ:BNTX | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.24 | 4.47% | 122.38 | 120.01 | 124.00 | 124.37 | 118.25 | 118.25 | 870,908 | 00:15:44 |
From Feb 2023 to Feb 2025
By Dean Seal
Shares of CureVac fell to an all-time low after the company said a German federal court has denied the validity of an intellectual property patent related to messenger ribonucleic acid technology in Covid-19 vaccines.
The stock dropped 41% to a low of $3.41 on Tuesday. Shares have fallen by a third since the start of the year.
The German biopharmaceutical company said the German Federal Patent Court granted a nullity action filed against CureVac's patent by rival BioNTech.
The two competitors are in ongoing patent litigation involving eight CureVac intellectual property rights. Proceedings regarding the seven remaining rights will be decided individually.
CureVac said it will appeal the German court's decision.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 19, 2023 11:57 ET (16:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year BioNTech Chart |
1 Month BioNTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
